Q2 2025 Indoco Remedies Ltd Earnings Call Transcript
Key Points
- Indoco Remedies Ltd (BOM:532612) celebrated 77 years of excellence in providing quality medicines.
- The company's key brand, Cyclopalm, has crossed a prescriber base of 1 lakh and is growing at close to 20%.
- Indoco received final ANDA approval from USFDA for Lofexidine tablets with 180 days exclusivity.
- The company launched new products in the dental ethical segment and acute division, expanding its product portfolio.
- Indoco's contract research organization, Anacypher CRO, has expanded its offerings with new pharmacovigilance services.
- Net revenues for the second quarter showed muted growth, with only a slight increase from the previous quarter.
- EBITDA to Net Sales decreased to 13.4% from 15.6% compared to the same quarter last year.
- International business revenues declined significantly, particularly in the US and Europe markets.
- The company is facing challenges with its sterile unit, impacting its ability to supply products internationally.
- Increased other expenses, particularly in sales promotional activities, have impacted financial performance.
Ladies and Gentlemen, Good day and welcome to Indoco Remedies Q2 FY25 Earnings Conference Call hosted by Dolat Capital. As a reminder, all participants' lines will be in the listen-only mode and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during the conference call, please signal an operator by pressing star and zero on your touchtone phone. Please note that this conference is being recorded. I now hand the conference over to Ms. Rashmi Shetty from Dolat Capital. Thank you and over to you ma'am.
Thank you Shissa. Good afternoon everyone. I, Rashmi Shetty, on behalf of Dolat Capital, welcome you all on the Q2 FY25 earnings firm call of Indoco Remedies. I would like to thank the management of Indoco Remedies for giving us this opportunity to host the call. Today, from the management team, we have with us Ms. Aditi Panandikar, Managing Director, Mr. Sundeep Bambolkar, Joint MD, and Mr. Pramod Ghorpade, CFO. I now hand over the call to the management for the opening remarks. Over to you,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
